Brain Glucose Responses Diminish With Diabetes, Obesity

Share this content:
Brain Glucose Responses Diminish With Diabetes, Obesity
Brain Glucose Responses Diminish With Diabetes, Obesity

MONDAY, Nov. 20, 2017 (HealthDay News) -- The rise of brain glucose levels is blunted during hyperglycemia in adults with obesity and type 2 diabetes mellitus (T2DM), according to a study published online Oct. 19 in JCI Insight.

Janice J. Hwang, M.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted 1H magnetic resonance spectroscopy scanning of the occipital lobe to measure the change in intracerebral glucose levels during a two-hour hyperglycemic clamp (glucose ~220 mg/dl) among 25 participants (nine healthy participants, 10 obese participants without diabetes, and six patients with poorly controlled, insulin- and metformin-treated T2DM).

The researchers found that after they controlled for age and sex, despite similar plasma glucose levels at baseline and during hyperglycemia, the change in intracerebral glucose was significantly different across groups. Brain glucose increments were lower in participants with obesity and T2DM compared with lean participants. In addition, during hyperglycemia, the change in brain glucose was inversely correlated with plasma free fatty acid levels.

"These data suggest that obesity and poorly controlled T2DM progressively diminish brain glucose responses to hyperglycemia, which has important implications for understanding not only the altered feeding behavior, but also the adverse neurocognitive consequences associated with obesity and T2DM," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »